Please use this identifier to cite or link to this item:
Author(s): Pinto, P.
Machado, C.M.
Moreira, J.
Almeida, J.D.P.
Silva, P.M.A.
Henriques, A.C.
Soares, J.X.
Salvador, J.A.R.
Afonso, C.
Pinto, M.
Bousbaa, H.
Cidade, H.
Title: Chalcone derivatives targeting mitosis: synthesis, evaluation of antitumor activity and lipophilicity
Publisher: European Journal of Medicinal Chemistry
Issue Date: 2019
Abstract: This study describes the synthesis of a series of chalcones, including pyrazole and a,b-epoxide de- rivatives, and evaluation of their cell growth inhibitory activity in three human tumor cell lines, as well as their lipophilicity using liposomes as a biomimetic membrane model. Structure-activity and structure- lipophilicity relationships were established for the synthetized chalcones. From this work, nine chal- cones (3, 5, 9, 11, 15e19) showing suitable drug-like lipophilicity with potent growth inhibitory activity were identified, being the growth inhibitory effect of compounds 15e17 associated with a pronounced antimitotic effect. Compounds 15e17 affected spindle assembly and, as a consequence, arrested cells at metaphase in NCIeH460 cells, culminating in cell death. Amongst the compounds tested, compound 15 exhibited the highest antimitotic activity as revealed by mitotic index calculation. Moreover, 15 was able to enhance chemosensitivity of tumor cells to low doses of paclitaxel in NCIeH460 cells. The results indicate that 15 exerts its antiproliferative activity by affecting microtubules and causing cell death subsequently to a mitotic arrest, and thus has the potential for antitumor activity.
Subject: Antitumor activity
Paclitaxel chemosensitivity
Source: European Journal of Medicinal Chemistry 184 (2019) 111752
Document Type: Artigo em Revista Científica Internacional
Rights: restrictedAccess
Appears in Collections:CIIMAR - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
  Restricted Access
2.06 MBAdobe PDF    Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.